• Lusvertikimab (OSE-127), a ‘first-in-class’ product, is the most clinically advanced anti-IL-7R monoclonal antibody.
• Ongoing phase 2 trial in ulcerative colitis (sponsor OSE Immunotherapeutics) after a positive futility analysis and according to the following inflection points:
o End of recruitment: Q3 2023.
o First results of the induction phase: December 2023.
o Early maintenance data after 6 months of treatment: H1 2024.
• OSE Immunotherapeutics holds full worldwide rights to Lusvertikimab.
• Strategic review of market opportunities for Lusvertikimab in Acute Lymphoblastic Leukemia based on positive preclinical efficacy data (2022 price from the “American Society of Hematology”).